

**BOLAGSSTÄMMA**

**2024-10-31**




***DexTech***

*Know-how in Translational Research*

# What We Do



## Translational Research



## Clinical Research

- SomaDex phase I, 2003 (mCRPC, Renal cell Cancer)
- Somadex, pilot study, 2008 (palliative mCRPC)
- ODX, phase I, 2013 (mCRPC)
- ODX, phase II, 2020 (mCRPC)
- ODX, phase I, 2023 (multiple myeloma)

# Our Portfolio

Candidates	Target Indications	Discovery	Preclinical	Clinical	Status
<b>OsteoDex™</b>	<ul style="list-style-type: none"> <li>• Castration Resistant Prostate Cancer (mCRPC)</li> <li>• Multiple Myeloma (MM)</li> </ul>				<ul style="list-style-type: none"> <li>• Completed Ph. IIb<sup>1</sup></li> <li>• Ph. I/IIb to begin 2023</li> </ul>
<b>PSMADex™</b>	<ul style="list-style-type: none"> <li>• Castration Resistant Prostate Cancer (mCRPC)</li> </ul>				<ul style="list-style-type: none"> <li>• In vitro/in vivo data<sup>2</sup></li> </ul>
<b>SomaDex™</b>	<ul style="list-style-type: none"> <li>• Castration Resistant Prostate Cancer (mCRPC)</li> <li>• Neuroendocrine tumors</li> </ul>				<ul style="list-style-type: none"> <li>• Completed Ph. Ia/b</li> <li>• Preclinical</li> </ul>

1: *European Journal of Cancer* 181 (2023) 198e207

# Activities, October-22-October-23

- ❖ Tech. batch synthesis & analysis
- ❖ Updating GMP batch protocols
- ❖ GMP production, ~500 doses...
- ❖ Analysis method validations
- ❖ IMPD updating
- ❖ IMPD submission & approval MPA
- ❖ GMP batch analysis
- ❖ Release GMP batch
- ❖ Delivery of study material to sites
- ❖ Amendment of study protocol & approval MPA, EPM
- ❖ New patent application, submitted to European patent office (Epo.org.)

# Activities, October-23-October-24

- ❖ Patient recruitment, Myeloma study
- ❖ PCT application, GMP-Synthesis
- ❖ Amendment Myeloma study
- ❖ New Method Development, Batch analysis
- ❖ Analysis & method validations, ODX manufacture
- ❖ IMPD updating
- ❖ New vendors, GMP batch analysis
- ❖ Set up VDR
- ❖ Partner Discussions:            -Venture Capital Organizations  
                                             -Pharma Companies

# Our Goals in 12 months

- ❖ **ODX, indication mCRPC ; Secure clinical development through Partnership**
- ❖ **ODX, indication multiple myeloma;  
Finalize Study**
- ❖ **Submit PCT application, GMP-Synthesis**

# Our Indications

❖ **Prostate Cancer**

❖ **Multiple Myeloma**

**(Sten Nilsson)**